"The U.S. Food and Drug Administration today approved the first generic versions of Aciphex (rabeprazole sodium) delayed-release tablets, used to treat gastroesophageal reflux disease (GERD) in adults and adolescents (ages 12 and up).
Single intravenous doses of PREVACID at 218 mg/kg in mice (approximately 30 times the recommended human dose based on BSA) and 167 mg/kg in rats (approximately 46 times the recommended human dose based on BSA) were lethal. The symptoms of acute toxicity were decreased locomotor response, ataxia, ptosis and tonic convulsions.
PREVACID is not removed from the circulation by hemodialysis.
PREVACID I.V. (lansoprazole for injection) for Injection is contraindicated in patients with known severe hypersensitivity to any component of the formulation.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 7/11/2007
Additional Prevacid I.V. Information
- Prevacid I.V. Drug Interactions Center: lansoprazole iv
- Prevacid I.V. Side Effects Center
- Prevacid I.V. Overview including Precautions
- Prevacid I.V. FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.